Vision 2028: How China could impact the global biopharma industry

McKinsey Public & Social Sector Insights

China-originated biopharmas will likely have greater influence on the industry by 2028, but regulatory developments and the quality of partnerships will determine how the industry grows.

Innovation sourcing in biopharma: Four practices to maximize success

McKinsey

Biopharma companies’ pipelines are full of assets they source externally to access innovation. Four practices will help ensure their investments flourish at a time of fierce competition. Insights on Life Sciences Pharmaceuticals Biotechnology Artificial Intelligence

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

The dawn of China biopharma innovation

McKinsey

Chinese biopharma is making a mark on the global stage as the rapidly evolving regulatory landscape and maturing innovation ecosystem spur significant value creation.

Leveraging digital and analytics in biopharma operations: Six principles

McKinsey

To maximize its benefits, biopharma companies can follow six principles. Digital and analytics is a powerful tool for transforming operational performance. Insights on Operations Analytics Operations

Integrated evidence generation: A paradigm shift in biopharma

McKinsey

Biopharma companies should consider a new, integrated approach to evidence-generation strategies to better demonstrate the value of therapies to all stakeholders.

Transforming biopharma R&D at scale

McKinsey

Transformations often struggle to scale up and make change stick. To achieve lasting impact, high-performing R&D organizations pay heed to the five outcomes that matter most. Insights on Life Sciences Pharmaceuticals

Reflections on 2020 ASAP BioPharma Conference: The right mindset is more important than ever

Vantage Partners

Overview The 2020 ASAP BioPharma conference came to a close a month ago and marked another year of bringing together talented and thoughtful strategic alliance professionals to share and reflect on their experiences in this field.

O’Dwyer’s PR News: “The Biopharma Communications Balancing Act”

LaVoie Health Science Blog

The post O’Dwyer’s PR News: “The Biopharma Communications Balancing Act” appeared first on LaVoie Health Science. LaVoieHealthScience President and CEO, Donna LaVoie , contributed to the O’Dwyer’s PR News Magazine October issue focused on healthcare and medical public relations.

Life Sciences’ Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all End Users

Frost & Sullivan

Over the next two to three years, biopharma companies also will highly invest in DTx solutions, enabling the subsidized cost to patients in exchange for marketing and access to patient data.

Life Sciences’ Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all End Users

Frost & Sullivan

Over the next two to three years, biopharma companies also will highly invest in DTx solutions, enabling the subsidized cost to patients in exchange for marketing and access to patient data.

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Frost & Sullivan

Healthcare News Press Releases biopharma biopharmaceutical biotechnology biotherapeutics COVID-19 vaccine logistics DNA drug mrna pharma Pharmaceutical research RNA therapeutics vaccine

Discover Six Dynamic Trends to Disrupt the Next Generation of Biopharmaceutical Manufacturing

Frost & Sullivan

Healthcare News Press Releases White Papers Analytics biopharma biopharmaceutical chemistry Manufacturing technology therapies

Optimizing Your Alliance Management Operating Model: Considerations from CHI's 2020 Strategic Alliance Management Congress

Vantage Partners

As in the past, this conference featured insightful presentations from leaders across Biopharma alliance management. Vantage Partners was proud to be the premier sponsor for Cambridge HealthTech Institute’s (CHI) 2020 Strategic Alliance Management Congress.

7 Reasons Why PPD’s Acquisition will Help TMO Gain a Top Spot in the CRO Market

Frost & Sullivan

2 – The consolidation of PPD with TMO’s Patheon manufacturing unit creates a compelling end-to-end offering for biopharma sponsors and an opportunity to cross-sell services through revenue stream synergies.

LHS Expert Insights: ESG Issues for Life Science Innovators

LaVoie Health Science Blog

What are some of the unique considerations that biopharma and life science firms must consider in mapping out their ESG strategies? Certainly few industries have received more scrutiny over the past year than biopharma.

2021 Preview: A 360-Degree Global Market View

LaVoie Health Science Blog

Panelists, including myself as moderator, consisted of industry leaders, including Dr. Alexandra Goll, Managing Director of Biopharma Advisory; Brad Loncar, CEO of Loncar Investments; and Amit Munshi, President, CEO and Board Member of Arena Pharmaceuticals.

LaVoieHealthScience Bolsters Commercial Strategic Communications Expertise with the Hiring of Deborah Plumstead as Vice President

LaVoie Health Science Blog

Plumstead brings expertise in commercial strategic communications programming and execution from pharma to biopharma and beyond.

IEEE-ISTO Announces a New Alliance to Advance Clinical Research Data Sharing

ISTO / IEEE

A group of leading BioPharma companies, academic institutions, and non-profit data-sharing platforms have come together to establish the Clinical Research Data Sharing Alliance (CRDSA). PISCATAWAY, N.J.,

The Importance of Natural History Data for Clinical Trial Development in Rare and Orphan Diseases

LaVoie Health Science Blog

The late Summer and early Fall have been busy with the very well-attended 42nd Canaccord Genuity Growth Conference in August, along with Citi’s 19th Annual BioPharma and Wells Fargo’s 2022 Healthcare Conferences in early September.

BTD BRINGS M&A DISCIPLINES TO ASAP

BTD Consulting

ASAP global, corporate, and individual members represent a wide variety of industries that include high tech, biopharma, life science, finance, fintech, insurance, energy, consulting, and many others. Leading alliances to the next level requires more than doing the same things better.

Technology Innovations and Virtual Consultations Drive the Healthcare Industry Transformation by 2025

Frost & Sullivan

Biopharma companies should partner with niche AI and data vendors to expedite drug design and development to reduce internal R&D risks for personalized therapies. Global healthcare revenues in 2025 will exceed $2.6 trillion propelled by AI and telehealth, finds Frost & Sullivan.

BTD brings M&A to ASAP

BTD Consulting

ASAP global, corporate, and individual members represent a wide variety of industries that include high tech, biopharma, life science, finance, fintech, insurance, energy, consulting, and many others. Leading alliances to the next level requires more than doing the same things better. Alliance management practice can be complemented by analytic rigor, systems logic, and AI. BTD brings this expertise to the ASAP partnership for the benefit of all its members.

Technology Investments will Help Oncology Practices Succeed in Value-based Care

Frost & Sullivan

Cardinal Health Specialty Solutions is a leading provider of technology and distribution solutions to specialty healthcare practices and biopharma manufacturers. Frost & Sullivan’s latest article highlights steps to transition to an Oncology Care First model. SANTA CLARA, Calif. –

Is the Potential Threat of Shareholder Activism Heightened by the Pandemic?

LaVoie Health Science Blog

And is your company prepared for what may be coming next?